跳转至内容
Merck
CN

Y0001084

用于系统适应性的乙酰唑胺

European Pharmacopoeia (EP) Reference Standard

别名:

乙酰唑胺, 5-乙酰胺基-1,3,4-噻二唑-2-磺酰胺, N-(5-[氨基磺酰基]-1,3,4-噻二唑-2-基)乙酰胺, N-(5-氨磺酰基-1,3,4-噻二唑-2-基)乙酰胺

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C4H6N4O3S2
化学文摘社编号:
分子量:
222.25
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)

SMILES string

CC(=O)Nc1nnc(s1)S(N)(=O)=O

InChI key

BZKPWHYZMXOIDC-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

acetazolamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

碳酸酐酶抑制剂;增加脑血流量。

Biochem/physiol Actions

通过与水通道蛋白相互作用抑制膜的水渗透性

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A S Vagal et al.
AJNR. American journal of neuroradiology, 30(5), 876-884 (2009-02-28)
The acetazolamide (ACZ) challenge test is a useful clinical tool and a reliable predictor of critically reduced perfusion. In patients with chronic steno-occlusive disease, the ability to maintain normal cerebral blood flow by reducing vascular resistance secondary to autoregulatory vasodilation
Emma V Low et al.
BMJ (Clinical research ed.), 345, e6779-e6779 (2012-10-20)
To assess the efficacy of three different daily doses of acetazolamide in the prevention of acute mountain sickness and to determine the lowest effective dose. Systematic review and meta-analysis. Medline and Embase along with a hand search of selected bibliographies.
Neil D Ritchie et al.
Journal of travel medicine, 19(5), 298-307 (2012-09-05)
Acetazolamide has been reported to be effective in the prevention of acute mountain sickness (AMS). Our aim was to conduct a systematic review of randomized, placebo-controlled trials of acetazolamide in the prevention of AMS. Studies were identified by searching the
Bengt Kayser et al.
High altitude medicine & biology, 13(2), 82-92 (2012-06-26)
Acetazolamide is used to prevent acute mountain sickness (AMS). We assessed efficacy and harm of acetazolamide for the prevention of AMS, and tested for dose-responsiveness. We systematically searched electronic databases (until April 2011) for randomized trials comparing acetazolamide with placebo
Gladys E Granero et al.
Expert opinion on drug delivery, 7(8), 943-953 (2010-06-23)
Acetazolamide (ACZ), a carbonic anhydrase inhibitor (CAI), and other oral CAIs have been an integral part of antiglaucoma therapy for > 40 years. ACZ is used orally for the reduction of intraocular pressure in patients suffering from glaucoma. However, this

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持